EDAP TMS S.A. (EDAP) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong growth in the core HIFU business, with record revenue and significant increases in HIFU revenue and placements. The strategic financing with EIB and the new CPT code for BPH treatment are positive developments. Although there are concerns about the declining noncore business and operating losses, the optimistic guidance and strategic investments in HIFU suggest a positive outlook. The Q&A session confirmed positive trends in U.S. procedures and payer coverage. Overall, these factors indicate a likely positive stock price movement.
Key Financial Performance
Global Revenue USD 16.1 million, marking the second consecutive quarter with record overall quarterly revenue for the respective period.
HIFU Revenue USD 7.7 million, representing a 57% increase compared to the third quarter of last year. This growth reflects consistent commercial execution, expanding clinical adoption, and growing recognition of the value Focal One Robotic HIFU brings to patients, physicians, and hospitals.
Focal One Placements 8 placements (6 capital sales and 2 operating leases), representing growth of 167% compared to the same period 1 year ago. This reflects growing confidence hospitals have in adopting Focal One Robotic HIFU as an integral cornerstone of their prostate cancer program.
Focal One Procedures in the U.S. Grew more than 15% year-over-year, reflecting growing clinical adoption of Focal One combined with the impact of sustained investment in market access initiatives.
Total Revenue (EUR) EUR 13.9 million, an increase of 6% compared to EUR 13.1 million for the same period in 2024.
Total HIFU Revenue (EUR) EUR 6.7 million, a 49% year-over-year increase compared to EUR 4.5 million for the third quarter of 2024. This was driven by 6 Focal One capital sales versus 3 in the prior year period and a 26% year-over-year increase in Focal One treatment-driven revenue.
Gross Profit (EUR) EUR 6 million, compared to EUR 5.2 million for the same period a year ago. Gross margin increased to 43% from 39.4% year-over-year, primarily due to the strategic shift to the high-margin HIFU business segment.
Operating Expenses (EUR) EUR 10.9 million, compared to EUR 11 million for the same period in 2024.
Operating Loss (EUR) EUR 4.9 million, approximately EUR 1 million lower compared to EUR 5.8 million in the third quarter of 2024.
Net Loss (EUR) EUR 5 million or EUR 0.13 per share, a EUR 1.4 million improvement compared to a net loss of EUR 6.4 million or EUR 0.17 per share in the same period a year ago.
Inventory (EUR) Decreased to EUR 13.8 million in Q3 compared to EUR 15.5 million in the prior quarter, due to continued efforts and focus on just-in-time inventory management.
Cash and Cash Equivalents (EUR) EUR 10.6 million at the end of Q3 2025, compared to EUR 16.3 million in the prior quarter. The sequential decrease was driven primarily by cash used in operating activities to support strategic investments in HIFU.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Focal One Robotic HIFU: Achieved record HIFU revenue of USD 7.7 million in Q3 2025, a 57% increase YoY. Placed 8 Focal One units, including 6 capital sales and 2 operating leases, marking a 167% growth YoY. Integrated into 21 of 35 SUO-approved fellowship programs, representing 60% of such centers nationwide.
Endometriosis Treatment: Phase III RCT data showed significant symptom improvement at 3 months, maintained at 1 year. Over 85% of sham group patients opted for HIFU post-unblinding, reporting significant symptom improvement. Limited commercial launch in Europe underway.
Market Access and Reimbursement: Achieved meaningful progress in reimbursement coverage, particularly with Medicare Advantage providers, driving broader patient access and stronger hospital economics.
Expansion into BPH Treatment: Progressing Phase I/II study in Europe and received IRB approval for U.S. study in partnership with Mount Sinai. First patient enrollment expected by year-end.
Revenue Growth: Global revenue reached USD 16.1 million in Q3 2025, marking the second consecutive quarter of record revenue. HIFU business revenue grew 49% YoY, offsetting declines in noncore businesses.
Operational Efficiencies: Improved manufacturing efficiencies, optimized supply chain, and transitioned to a new ultrasound imaging scanner supplier to reduce costs in the upcoming year.
Strategic Focus on HIFU: Shifted focus to high-margin HIFU business, contributing to increased gross margins (43% in Q3 2025 vs. 39.4% in Q3 2024).
Recognition and Awards: Focal One received the 2025 Industry Award for innovations in Endourological Instrumentation at the WCET meeting.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Impact: The company is forecasting a 15% tariff impact for all goods transferred between France and the U.S., with a year-to-date impact of approximately EUR 300,000 and an estimated full-year impact of EUR 900,000. This could affect profitability and operational costs.
Cash and Cash Equivalents: Total cash and cash equivalents decreased to EUR 10.6 million at the end of Q3 2025 from EUR 16.3 million in the prior quarter, primarily due to cash used in operating activities to support strategic investments in HIFU. This reduction in liquidity could constrain future investments or operational flexibility.
Decline in Noncore Businesses: Revenue from noncore distribution and ESWL businesses declined by 16% in Q3 2025 compared to Q3 2024, and is expected to decline by 25% to 30% year-over-year. This ongoing decline could impact overall revenue diversification and stability.
Operating Loss: The company reported an operating loss of EUR 4.9 million for Q3 2025, which, while an improvement from the prior year, still represents a significant financial challenge.
Inventory Management: Inventory decreased to EUR 13.8 million in Q3 2025 from EUR 15.5 million in the prior quarter due to just-in-time inventory management. While this improves efficiency, it could pose risks if demand unexpectedly spikes.
Supplier Transition: The company is transitioning to a new supplier for its ultrasound imaging scanner, which is expected to reduce costs in the upcoming calendar year. However, this transition could pose short-term risks to supply chain stability and product availability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Core HIFU Business Revenue Growth: Expected to grow within the range of 26% to 34% year-over-year in 2025.
Noncore ESWL and Distribution Business Revenue Decline: Expected to decline within the range of 25% to 30% year-over-year in 2025.
U.S. Procedure Growth: Return to double-digit growth in Focal One procedures in the U.S. is expected to continue.
Market Access and Reimbursement Coverage: Continued expansion in market access and reimbursement coverage, particularly among Medicare Advantage providers, is anticipated to drive broader patient access and stronger hospital economics.
BPH Clinical Development Program: Progressing with a Phase I/II multicenter study in Europe and a U.S. clinical study in partnership with the Icahn School of Medicine at Mount Sinai. The first patient enrollment in the U.S. study is expected before the end of 2025.
Endometriosis Treatment Expansion: Actively working with leading European centers in a limited launch phase to establish a foundation for expanded adoption of Focal One HIFU as a noninvasive treatment option for deep infiltrating endometriosis.
Cost Reduction Impact: Transition to a new supplier for ultrasound imaging scanners is expected to result in cost reductions in the upcoming calendar year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the purpose of the EIB deal and how will the proceeds be used?
A:The proceeds from the EIB deal will be used across three main areas: product development (including R&D), clinical development (expanding new indications), and commercial growth. The focus is centered around the HIFU core business. The EIB was chosen as the most attractive financing option due to its lack of short-term stock dilution and the stock's trading performance over the last 180 days.
Q:Can you comment on the double-digit increase in U.S. Focal One procedures and the coverage of these procedures?
A:The increase in U.S. Focal One procedures includes a mix of Medicare patients, Medicare Advantage plan patients, and commercial patients. There has been improvement across payers representing Medicare Advantage plans, which is a positive trend. The company expects to continue driving momentum and activity in this area.
Q:What are the expectations for the fourth quarter, given that the third quarter is typically seasonally soft?
A:The company reiterated its guidance for the year, expecting revenue between $58 million and $62 million for CY '25. While no quarterly guidance is provided, they are confident that the Q4 numbers will align with these year-end targets.
Q:Review of Unclear Management Responses
A:No questions were directly avoided, but some responses lacked specific numerical details, such as the exact number of U.S. Focal One procedures covered or precise quarterly expectations for Q4.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advantage
BPH
EDAP TMS
EUR decrease
EUR increase
EUR loss
EUR month
EUR period
EUR share
Endourological
FARP
HIFU EUR
HIFU group
HIFU treatment
Phase III
USD
adoption Focal
award
cancer survival
capital sale
core HIFU
economics
foundation
group improvement
hospital physician
improvement symptom
loss EUR
loss month
month EUR
month HIFU
patient sham
period EUR
period loss
presence urology
radiation therapy
sham group
therapy technology
treatment group
user
EDAP Transcript
EDAP TMS S.A. (EDAP) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call lacked forward-looking statements and strategic initiatives, providing no guidance or market trends, which is typically negative. However, the company reported strong financial performance with increased revenue, gross margin, and net income. The absence of negative Q&A insights further stabilizes the outlook. Without a market cap, we assume a moderate response, resulting in a neutral sentiment.
EDAP TMS S.A. (EDAP) Q4 2025 Earnings Call Transcript
Positive3-25
The earnings call highlights strong financial performance with a 12% revenue increase, improved gross margins, and a 40% rise in net income. Despite regulatory compliance risks, the financial metrics are robust, indicating positive market sentiment. The absence of strategic updates or operational concerns further supports a positive outlook.
EDAP TMS S.A. (EDAP) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reflects strong growth in the core HIFU business, with record revenue and significant increases in HIFU revenue and placements. The strategic financing with EIB and the new CPT code for BPH treatment are positive developments. Although there are concerns about the declining noncore business and operating losses, the optimistic guidance and strategic investments in HIFU suggest a positive outlook. The Q&A session confirmed positive trends in U.S. procedures and payer coverage. Overall, these factors indicate a likely positive stock price movement.
EDAP TMS S.A. (EDAP) Q2 2025 Earnings Conference Call Transcript
Positive8-28
The earnings call reveals strong financial performance with a 76.8% increase in HIFU revenue and improved gross margins. Despite operating and net losses, strategic investments in HIFU and efficient inventory management are promising. Positive Q&A insights include efforts to improve reimbursement, growing demand, and multiunit purchases, indicating confidence in future growth. However, some concerns remain about reimbursement and unclear management responses. Overall, the company's strategic focus and optimistic guidance point to a positive stock price movement.
EDAP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
